ClinicalTrials.gg
RecruitingNCT05914545Updated Aug 28, 2026

A Study of FZ-AD004 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of FZ-AD004 in Advanced and Metastatic Solid Tumor, sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.. Recruiting at 3 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
121
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 486 studies in Neoplasm Metastasis with a site in China — 223 open to participants now, 263 under way, 40 of them phase 3. Neoplasm Metastasis · China.

Planned enrollment
168th of 402
121 · median 90
Started
2023
with 40 others
Phase 1
93 of 486
47 open now
Primary completion
2026-12
later than 101 of 262 live
Registered
282nd of 486
by date

Among the 486 studies in Neoplasm Metastasis with a site in China, this one is the 168th largest by planned enrollment of the 402 interventional ones that give a count, is one of 41 that started in 2023, is one of 93 in phase 1, reaches primary completion later than 101 of the 262 other live ones, and was the 282nd registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 893 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

223 of the 486 studies in Neoplasm Metastasis with a site in China are open now. Recruiting first, the newest first:

218 more — sign in →

All 223 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 693 Neoplasm Metastasis studies recruiting now, 541 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 486 studies in Neoplasm Metastasis with a site in China, or all of them as a file.
02

Study summary

This study is one single group of participants with advanced solid tumors. It is the first time the drug has been used in humans. There will be two parts including Dose Escalation and Dose Expansion to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of FZ-AD004.

Read the detailed description

This is a first-in-human (FIH), Phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of FZ-AD004 in patients with advanced/metastatic solid tumors. FZ-AD004 is administered via intravenous infusion using an accelerated titration method followed by a conventional 3 + 3 study design to identify the maximum tolerated dose (MTD) and dose-limiting toxicities(DLT)during cycle 1. In addition, the maximum-tolerated dose and recommended Phase II dose for FZ-AD004 will be determined.

03

Conditions studied

  • Advanced and Metastatic Solid Tumor

Browse trials for

Keywords

  • Advanced and Metastatic Solid Tumor
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients able to give written ;
  2. Age ≥ 18 and ≤ 75 years old, male or female;
  3. Patients have histological or cytological diagnosis with advanced solid tumors.
  4. Have defined in v. 1.1;
  5. Expected survival ≥ 12 weeks;
  6. Eastern Cancer Cooperative Group () performance status 0-1;
  7. Patients of child bearing potential must agree to take during the study and for 6 months after the last day of treatment.

Exclusion criteria

Exclusion Criteria:

  1. Have had other malignant tumors in the past 5 years;
  2. Have CNS (central nervous system) with clinical symptoms;
  3. Had undergone major surgery or severe trauma within 4 weeks prior to the first dose;
  4. Had undergone systemic high-dose within 2 weeks of initiation of study treatment;
  5. Have history of psychotropic drug abuse, alcohol or drug abuse;
  6. Women who are pregnant or lactating;
  7. Other circumstances that is deemed not appropriate for the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
121 participants (estimated)

Study arms

  • Experimental
    Experimental: FZ-AD004

    Participants enrolled in the dose escalation part or dose expansion part

    Drug: FZ-AD004

Interventions

  • DrugFZ-AD004

    Dose Escalation:Subjects will receive an intravenous infusion of FZ-AD004 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study. Dose Expansion:Subject will receive a single dose of FZ-AD004 at 1-2 dose level on Day1 of each cycles.

    Also known as: FZ-AD004-Antibody-drug Conjugate

06

What researchers measure

Primary outcomes

  1. The dose limiting toxicity ( DLT)

    To determine the dose limiting toxicities (DLTs) of FZ-AD004.

    Time frame: 21 Days (first cycle)

  2. Maximum Tolerable Dose (MTD)

    To determine the maximum tolerated dose (MTD) and/or recommended doses for expansion (RDEs). RDEs will not exceed MTD.

    Time frame: 21 Days (first cycle)

  3. Adverse Events

    To check the numbers of AEs happened during the course of trial.

    Time frame: Screening up to study completion

  4. Objective Response Rate (ORR) according to RECIST 1.1

    To evaluate the objective response rate (ORR) \[Complete Response (CR) + Partial Response (PR)\] of FZ-AD004 when administered intravenously (IV) as monotherapy at the RDEs to patients with metastatic or locally advanced unresectable tumors.

    Time frame: From subject randomization up to 60 months.

Secondary outcomes

  1. Progression free survival(PFS) according to RECIST 1.1

    Progression-free survival (PFS) was defined as the interval from the first dose start date to the date of disease progression defined as documented progressive disease (PD) or death from any cause, whichever occurs first.

    Time frame: From subject randomization up to 60 months.

  2. Duration of Response(DOR) according to RECIST 1.1

    Duration of Response was defined as the duration of overall response measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started).

    Time frame: From subject randomization up to 60 months

  3. Overall Survival (OS) according to RECIST 1.1

    Overall survival was defined as the time from the date of the first dose start date to the date of death due to any cause.

    Time frame: From subject randomization up to 60 months.

  4. Terminal elimination half-life (t1/2) of Total Antibody, Free DXd and FZ-AD004

    To check how much time Total Antibody, Free DXd and FZ-AD004 will take to eliminate half of it's concentration from participants.

    Time frame: Up to 17 weeks

  5. Maximum observed plasma concentration (Cmax) of Total Antibody, Free DXd and FZ-AD004

    o check what will be the maximum concentration participants will obtained of Total Antibody, Free DXd and FZ-AD004 in their blood plasma.

    Time frame: Up to 17 weeks

  6. Area under the concentration-time curve (AUC 0-∞) from time 0 to infinity of Total Antibody, Free DXd and FZ-AD004

    To check the drug profile for absorption, distribution, metabolism and excretion for Total Antibody, Free DXd and FZ-AD004 in participants blood plasma

    Time frame: Up to 17 weeks

  7. Time to Cmax (Tmax) of Total Antibody, Free DXd and FZ-AD004

    To check what time will it take to reach the maximum contraction of Total Antibody, Free DXd and FZ-AD004 in study participants

    Time frame: Up to 17 weeks

  8. Number of subjects who develop detectable anti-drug antibodies (ADAs)

    To check the" Anti Drug Antibody" develops in participants against the FZ-AD004 through blood sample

    Time frame: From subject randomization up to 60 months.

07

Study locations

3 of 3 sites recruiting
  • Zhejiang Cancer Hospital
    Hangzhou, China
    Recruiting
    • Yongling Ji · Contact
    • Yongling Ji · Principal investigator
    • Zhengbo Song · Sub investigator
  • Shanghai Chest Hospital, Shanghai Jiaotong University, School of Medicine
    Shanghai, China
    Recruiting
    • Shun Lu · Contact
    • Shun Lu · Principal investigator
  • Hospital of Xuzhou Medical University
    Xuzhou, China
    Recruiting
    • Zhengxiang Han · Contact
    • Zhengxiang Han · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Dec 2026, 42 months after the start.

Of 288 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's planned 42 months is below that.

Counting every sponsor, half of 498 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2023
First posted
Jun 22, 2023
StartActual
Jun 21, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05914545
Responsible party
Sponsor
First posted
Jun 22, 2023
Start date
Jun 21, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Aug 28, 2026

Study contacts

Xuejing Cheng
Contact
xjcheng@fd-zj.com
00-86-021-58953355

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion